Clearpoint Neuro is trading 6.03% down at $10.05 after a revenue miss and reduced 2026 outlook.
- October 28 results: revenue was $12.1 million versus $12.5 million consensus; quarterly loss per share beat estimates.
- Management set 2026 revenue guidance at $48 million to $50 million, below the original $52 million to $56 million range.
- Nasdaq was down 2.24% pre-market; no separate Clearpoint Neuro announcement dated October 30 surfaced in search results.